A systematic review and network meta - analysis of pharmacological therapies used for patients with advanced Parkinson's disease (2014)

Parkinson’s disease affects about 110,000 people in the UK and 1.25 million people in Europe.1 Current options for management of advanced Parkinson’s disease include:

• Increased dose or frequency of immediate-release levodopa (IR LD)

• Supplemental controlled-release levodopa (CR LD)

• Adjunctive therapies with levodopa, including dopamine agonists, monoamine oxidase-B inhibitors (MAO-BIs), and catechol-O-methyl transferase inhibitors (COMTIs) A new modified release form of levodopa (IPX066) is in development.